Hepatic Cirrhosis Clinical Trial
Protean is seeking sites to enroll patients and participate in a clinical trial regarding blood testing to detect liver cancer. Subjects include those with cirrhosis of any etiology or chronic Hepatitis B without cirrhosis.
(Please email skyler.keller@proteanbiodx.com for a full request criteria list)
Cerebral Cavernous Malformation Clinical Trial
Protean is seeking sites to enroll patients and participate in a clinical trial regarding the safety, tolerability, and efficacy of an investigational drug in patients with cerebral cavernous malformation (CCM). Patients must be willing to participate in an MRI.
(Please email skyler.keller@proteanbiodx.com for a full request criteria list)
Bacterial Infection Diagnostic Test Clinical Trial
Protean is seeking sites to enroll study subjects presenting for acute respiratory infection, trained test users, untrained test users, and participate in a clinical trial regarding a candidate diagnostic test. This will include paired fingerstick blood samples collected from the patient by both trained and untrained users.
(Please email skyler.keller@proteanbiodx.com for a full request criteria list)
Prostate Clinical Trial
Protean is seeking sites to enroll patients and participate in a clinical trial regarding diagnostic blood testing in men who have not been diagnosed prior with any cancer with elevated PSA.
(Please email skyler.keller@proteanbiodx.com for a full request criteria list)
Colorectal Clinical Trial
Protean is seeking sites to enroll patients and participate in a clinical trial regarding collecting condensed exhaled breath samples from patients who are at average risk for development of colorectal cancer warranting diagnostic colonoscopy. Both genders aged 65-84 years preferred. Patients who have been diagnosed with a condition that is associated with high risk for colorectal cancer are not eligible .
(Please email skyler.keller@proteanbiodx.com for a full request criteria list)
This is a liquid biopsy study, evaluating the accuracy of blood proteomic analysis to predict cancer response to immunotherapy. The goal is to develop blood tests that will more accurately predict if a patient with lung cancer or advanced melanoma will respond to potentially toxic and costly immunotherapy treatments.
For more information on our clinical trials, please contact our research manager Hannah Park :
Email: hannah.park@proteanbiodx.com
